2009
DOI: 10.1016/j.bbapap.2008.12.010
|View full text |Cite
|
Sign up to set email alerts
|

Stability improvement of the fatty acid binding protein Sm14 from S. mansoni by Cys replacement: Structural and functional characterization of a vaccine candidate

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
23
0

Year Published

2009
2009
2013
2013

Publication Types

Select...
6
2
1

Relationship

1
8

Authors

Journals

citations
Cited by 30 publications
(24 citation statements)
references
References 37 publications
1
23
0
Order By: Relevance
“…Intrinsic tryptophan fluorescence was measured with an excitation wavelength set at 285 nm and emission spectra were recorded in the spectral range 310-400 nm. 68 Alternatively, thermal unfolding studies were carried out in the presence of 8 μM ANS. The temperature range tested was between 20 and 70°C.…”
Section: Spectroscopic and Protein Stability Studiesmentioning
confidence: 99%
“…Intrinsic tryptophan fluorescence was measured with an excitation wavelength set at 285 nm and emission spectra were recorded in the spectral range 310-400 nm. 68 Alternatively, thermal unfolding studies were carried out in the presence of 8 μM ANS. The temperature range tested was between 20 and 70°C.…”
Section: Spectroscopic and Protein Stability Studiesmentioning
confidence: 99%
“…To date, the fatty acid–binding proteins (FABP-Fh15 and Sm14) have been the only F. hepatica/S. mansoni –common proteins characterized and exploited as a potential dual-vaccine (Ramajo et al, 2001; Vilar et al, 2003; Ramos et al, 2009). However, because F. hepatica and S. mansoni are parasites with great antigenic complexity, it is expected that they possess common proteins other than FABPs that might contribute to serological cross-reactivity.…”
mentioning
confidence: 99%
“…To date, two candidate vaccines are in clinical trials, including Sh28GT targeting S. hematobium and Sm14 targeting S. mansoni. 5,6 The Sabin Vaccine Institute Product Development Partnership (PDP) is developing a recombinant vaccine comprised of the extracellular domain of the S. mansoni tetraspanin surface antigen known as Sm-TSP-2 ( Fig. 1).…”
Section: Introductionmentioning
confidence: 99%